Janux Therapeutics, Inc.
JANX
$23.64
$0.632.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -82.56% | 741.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -82.56% | 741.72% |
| Cost of Revenue | -- | 78.07% | 69.97% | 56.53% | -- |
| Gross Profit | -- | -95.47% | -112.74% | -93.87% | 164.16% |
| SG&A Expenses | 33.67% | 34.03% | 29.24% | 174.42% | 13.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.59% | 62.97% | 56.05% | 97.93% | 4.19% |
| Operating Income | -226.42% | -73.09% | -79.85% | -126.66% | 33.38% |
| Income Before Tax | -468.18% | -59.27% | -71.93% | -142.56% | 65.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -468.18% | -59.27% | -71.93% | -142.56% | 65.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -468.18% | -59.27% | -71.93% | -142.56% | 65.96% |
| EBIT | -226.42% | -73.09% | -79.85% | -126.66% | 33.38% |
| EBITDA | -234.76% | -75.14% | -82.69% | -130.73% | 34.33% |
| EPS Basic | -400.00% | -26.42% | -41.21% | -102.92% | 73.86% |
| Normalized Basic EPS | -399.71% | -26.42% | -41.23% | -102.91% | 73.85% |
| EPS Diluted | -400.00% | -26.42% | -41.21% | -102.92% | 73.86% |
| Normalized Diluted EPS | -399.71% | -26.42% | -41.23% | -102.91% | 73.85% |
| Average Basic Shares Outstanding | 13.68% | 25.98% | 21.74% | 19.52% | 30.15% |
| Average Diluted Shares Outstanding | 13.68% | 25.98% | 21.74% | 19.52% | 30.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |